![Guus van Scharrenburg](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Guus van Scharrenburg
Operationeel Directeur bij BiOrion Technologies BV
Actieve functies van Guus van Scharrenburg
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
BiOrion Technologies BV
![]() BiOrion Technologies BV Pharmaceuticals: GenericHealth Technology BiOrion Technologies BV develops therapeutic drugs for the cancer and inflammatory diseases. It operates as a pre-clinical stage biopharmaceutical company that developing targeted therapies and companion imaging diagnostics for personalized treatment of patients with fibrosis. The firm develops advanced personalized medicine drugs for simultaneous diagnosis and treatment of diseases such as liver- and pancreatic cancer, liver cirrhosis and kidney fibrosis through specific targeting to PDGF- and IGF-II-expressing diseased cells. The company was founded by Martin Hessing, Klaas Poelstra and Herman Steen in 2003 and is headquartered in Groningen, the Netherlands. | Operationeel Directeur | - | - |
Loopbaan van Guus van Scharrenburg
Statistieken
Internationaal
Nederland | 2 |
Operationeel
Chief Operating Officer | 1 |
Sectoraal
Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
BiOrion Technologies BV
![]() BiOrion Technologies BV Pharmaceuticals: GenericHealth Technology BiOrion Technologies BV develops therapeutic drugs for the cancer and inflammatory diseases. It operates as a pre-clinical stage biopharmaceutical company that developing targeted therapies and companion imaging diagnostics for personalized treatment of patients with fibrosis. The firm develops advanced personalized medicine drugs for simultaneous diagnosis and treatment of diseases such as liver- and pancreatic cancer, liver cirrhosis and kidney fibrosis through specific targeting to PDGF- and IGF-II-expressing diseased cells. The company was founded by Martin Hessing, Klaas Poelstra and Herman Steen in 2003 and is headquartered in Groningen, the Netherlands. | Health Technology |